Novo Nordisk (NVO) said Monday that its phase 3 trial evaluating CagriSema -- a fixed-dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg --met its primary endpoint in 1,206 overweight or obese patients with type 2 diabetes.
The trial showed a "statistically significant and superior weight loss" with CagriSema compared to placebo at week 68. Patients on CagriSema achieved a 15.7% weight loss, versus 3.1% in the placebo group, the company said.
Additionally, 89.7% of CagriSema-treated patients achieved at least 5% weight loss, which was a co-primary endpoint, compared with 30.3% with placebo.
Novo Nordisk said CagriSema was well-tolerated, with mostly mild to moderate gastrointestinal side effects.
The company plans to seek regulatory approval in Q1 2026.
Novo Nordisk shares were down more than 5% in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.